Analgesic Efficacy of Intravenous Ibuprofen in the Treatment of Postoperative Acute Pain: A Phase III Multicenter Randomized Placebo-ControlledDouble-Blind Clinical Trial

Objective. To evaluate the analgesic efficacy and safety of different does of intravenous ibuprofen (IVIB) in the treatment of postoperative acute pain. Methods. Patients with an intravenous (IV) patient-controlled analgesia device after abdominal or orthopedic surgery were randomly divided into pla...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pain Research and Management 2023-03, Vol.2023, p.7768704-12
Hauptverfasser: Zhou, Hong-Su, Li, Ting-Ting, Pi, Yu, Wang, Ting-Hua, Liu, Fei, Xiong, Liu-Lin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 12
container_issue
container_start_page 7768704
container_title Pain Research and Management
container_volume 2023
creator Zhou, Hong-Su
Li, Ting-Ting
Pi, Yu
Wang, Ting-Hua
Liu, Fei
Xiong, Liu-Lin
description Objective. To evaluate the analgesic efficacy and safety of different does of intravenous ibuprofen (IVIB) in the treatment of postoperative acute pain. Methods. Patients with an intravenous (IV) patient-controlled analgesia device after abdominal or orthopedic surgery were randomly divided into placebo, IVIB 400 mg, and IVIB 800 mg groups. The first dosage of study medicines was given intravenously 30 minutes (min) before surgery ended, followed by six hours (h) intervals for a total of eight doses following surgery. The demographic characteristics and procedure data, cumulative morphine consumption, the visual analog scale (VAS), the area under the curve (AUC) of VAS, patient satisfaction score (PSS), the rates of treatment failure (RTF), and adverse events (AEs) and serious adverse event (SAEs) were recorded during the period of trial. Result. A total of 345 patients were enrolled in the full analysis set (FAS), and of 326 participants were valid data set (VDS). Demographic characteristics, disease features, and medical history of patients were not significantly different between groups. Total morphine consumption of the IVIB 400 mg group (11.14 ± 7.14 mg; P = 0.0011) and the IVIB 800 mg group (11.29 ± 6.45 mg; P = 0.0014) was significantly reduced compared with the placebo group (14.51 ± 9.19 mg) for 24 h postoperatively, there was no significant difference between the IVIB 400 mg and IVIB 800 mg groups (P = 0.9997). The placebo group had significantly higher VAS and the AUCs of VAS than those in the IVIB 400 mg and the IVIB 800 mg groups at rest and movement for 24 h postoperatively (P  0.05). RTF was slightly higher in the placebo group than IVIB 400 mg group and 800 mg group, and no statistical significance (P  0.05) were not different among the three groups. Conclusion. Intermittent IV administration of ibuprofen 400 mg or 800 mg within 24 h after surgery in patients undergoing abdominal and orthopedic surgery significantly decreased morphine consumption and relieved pain, without increasing the incidence of AEs.
doi_str_mv 10.1155/2023/7768704
format Article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10014159</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A814686983</galeid><doaj_id>oai_doaj_org_article_75002afbaf964718b1f63ccaafcf1d52</doaj_id><sourcerecordid>A814686983</sourcerecordid><originalsourceid>FETCH-LOGICAL-c613t-5f2c1e4a7b6b24125aab5d9c185a0e72bcc15a84a9b3b76ed386830858a93ff33</originalsourceid><addsrcrecordid>eNp9kl1rFDEUhgdRbK3eeS0BQQSdNh_zkfFG1rXqQMVF6vVwJnOym5JN1mSmUn-Sv9KsW2tXRAJJSJ7znuScN8seM3rMWFmecMrFSV1XsqbFneyQNUzmrOTibtpzKvKqrsqD7EGMF5QWTFJxPzsQVcMrUTeH2Y-ZA7vEaBQ51dooUFfEa9K6McAlOj9F0vbTJniNjhhHxhWS84AwrtGNW3Lh4-g3GGA0l0hmahqRLMC4V2RGFiuISNq2JR8nOxqVQjCQz-AGvzbfcSALCwp7n899yuetxeGtn3qL-Rtr3EDmaU5PsimjAfswu6fBRnx0vR5lX96dns8_5Gef3rfz2VmuKibGvNRcMSyg7queF4yXAH05NIrJEijWvFeKlSALaHrR1xUOQlZSUFlKaITWQhxl7U538HDRbYJZQ7jqPJju14EPyw5C-o3Fri4p5aB70E1V1Ez2TFdCKQCtNBtSE46y1zutzdSvcdhWIIDdE92_cWbVLf1lxyhlBSubpPD8WiH4rxPGsVubqNBacJi60_FayropJS8S-vQv9MJPIfV3R3HR0IL_oZaQfmCc9imx2op2M8mKSlaN3Bbh-B9UGgOujfIOtUnnewHPbgWsEOy4it5Oo_Eu7oMvd6AKPsaA-qYajHZbR3dbR3fXjk74k9sVvIF_WzgBL3bAKlkGvpn_y_0Etf3-BQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2788239042</pqid></control><display><type>article</type><title>Analgesic Efficacy of Intravenous Ibuprofen in the Treatment of Postoperative Acute Pain: A Phase III Multicenter Randomized Placebo-ControlledDouble-Blind Clinical Trial</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Zhou, Hong-Su ; Li, Ting-Ting ; Pi, Yu ; Wang, Ting-Hua ; Liu, Fei ; Xiong, Liu-Lin</creator><contributor>Kim, Young-Kug ; Young-Kug Kim</contributor><creatorcontrib>Zhou, Hong-Su ; Li, Ting-Ting ; Pi, Yu ; Wang, Ting-Hua ; Liu, Fei ; Xiong, Liu-Lin ; Kim, Young-Kug ; Young-Kug Kim</creatorcontrib><description>Objective. To evaluate the analgesic efficacy and safety of different does of intravenous ibuprofen (IVIB) in the treatment of postoperative acute pain. Methods. Patients with an intravenous (IV) patient-controlled analgesia device after abdominal or orthopedic surgery were randomly divided into placebo, IVIB 400 mg, and IVIB 800 mg groups. The first dosage of study medicines was given intravenously 30 minutes (min) before surgery ended, followed by six hours (h) intervals for a total of eight doses following surgery. The demographic characteristics and procedure data, cumulative morphine consumption, the visual analog scale (VAS), the area under the curve (AUC) of VAS, patient satisfaction score (PSS), the rates of treatment failure (RTF), and adverse events (AEs) and serious adverse event (SAEs) were recorded during the period of trial. Result. A total of 345 patients were enrolled in the full analysis set (FAS), and of 326 participants were valid data set (VDS). Demographic characteristics, disease features, and medical history of patients were not significantly different between groups. Total morphine consumption of the IVIB 400 mg group (11.14 ± 7.14 mg; P = 0.0011) and the IVIB 800 mg group (11.29 ± 6.45 mg; P = 0.0014) was significantly reduced compared with the placebo group (14.51 ± 9.19 mg) for 24 h postoperatively, there was no significant difference between the IVIB 400 mg and IVIB 800 mg groups (P = 0.9997). The placebo group had significantly higher VAS and the AUCs of VAS than those in the IVIB 400 mg and the IVIB 800 mg groups at rest and movement for 24 h postoperatively (P &lt; 0.05), and there was no significant difference between the IVIB 400 mg and IVIB 800 mg groups (P &gt; 0.05). RTF was slightly higher in the placebo group than IVIB 400 mg group and 800 mg group, and no statistical significance (P &lt; 0.690). PSS in the IVIB 400 mg (P = 0.0092) and the IVIB 800 mg groups (P = 0.0011) was higher than the placebo group for pain management, there was also no significant difference between the IVIB 400 mg and IVIB 800 mg groups (P = 0.456). The incidence of RTF (P = 0.690) and AEs (P &gt; 0.05) were not different among the three groups. Conclusion. Intermittent IV administration of ibuprofen 400 mg or 800 mg within 24 h after surgery in patients undergoing abdominal and orthopedic surgery significantly decreased morphine consumption and relieved pain, without increasing the incidence of AEs.</description><identifier>ISSN: 1203-6765</identifier><identifier>ISSN: 1918-1523</identifier><identifier>EISSN: 1918-1523</identifier><identifier>DOI: 10.1155/2023/7768704</identifier><identifier>PMID: 36926379</identifier><language>eng</language><publisher>United States: Hindawi</publisher><subject>Acute Pain - drug therapy ; Acute Pain - etiology ; Analgesics ; Analgesics - therapeutic use ; Analgesics, Opioid - therapeutic use ; Anesthesia ; Blood pressure ; Bone surgery ; Clinical trials ; Dosage and administration ; Double-Blind Method ; Drug dosages ; Drug therapy ; Humans ; Ibuprofen ; Ibuprofen - therapeutic use ; Medical personnel ; Morphine ; Morphine - therapeutic use ; Narcotics ; Nausea ; Nervous system ; Nonsteroidal anti-inflammatory drugs ; Orthopedics ; Pain management ; Pain, Postoperative ; Pain, Postoperative - drug therapy ; Pain, Postoperative - etiology ; Patient satisfaction ; Pharmacology, Experimental ; Physiological aspects ; Postoperative period ; Pruritus ; Self evaluation ; Testing ; Urinary retention ; Vomiting</subject><ispartof>Pain Research and Management, 2023-03, Vol.2023, p.7768704-12</ispartof><rights>Copyright © 2023 Hong-Su Zhou et al.</rights><rights>COPYRIGHT 2023 John Wiley &amp; Sons, Inc.</rights><rights>Copyright © 2023 Hong-Su Zhou et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2023 Hong-Su Zhou et al. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c613t-5f2c1e4a7b6b24125aab5d9c185a0e72bcc15a84a9b3b76ed386830858a93ff33</citedby><cites>FETCH-LOGICAL-c613t-5f2c1e4a7b6b24125aab5d9c185a0e72bcc15a84a9b3b76ed386830858a93ff33</cites><orcidid>0000-0003-3337-8168 ; 0000-0002-2499-7605 ; 0000-0003-2012-8936 ; 0000-0002-1623-5969 ; 0000-0001-6041-6719 ; 0000-0002-9970-1338</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014159/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014159/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,878,886,27929,27930,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36926379$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Kim, Young-Kug</contributor><contributor>Young-Kug Kim</contributor><creatorcontrib>Zhou, Hong-Su</creatorcontrib><creatorcontrib>Li, Ting-Ting</creatorcontrib><creatorcontrib>Pi, Yu</creatorcontrib><creatorcontrib>Wang, Ting-Hua</creatorcontrib><creatorcontrib>Liu, Fei</creatorcontrib><creatorcontrib>Xiong, Liu-Lin</creatorcontrib><title>Analgesic Efficacy of Intravenous Ibuprofen in the Treatment of Postoperative Acute Pain: A Phase III Multicenter Randomized Placebo-ControlledDouble-Blind Clinical Trial</title><title>Pain Research and Management</title><addtitle>Pain Res Manag</addtitle><description>Objective. To evaluate the analgesic efficacy and safety of different does of intravenous ibuprofen (IVIB) in the treatment of postoperative acute pain. Methods. Patients with an intravenous (IV) patient-controlled analgesia device after abdominal or orthopedic surgery were randomly divided into placebo, IVIB 400 mg, and IVIB 800 mg groups. The first dosage of study medicines was given intravenously 30 minutes (min) before surgery ended, followed by six hours (h) intervals for a total of eight doses following surgery. The demographic characteristics and procedure data, cumulative morphine consumption, the visual analog scale (VAS), the area under the curve (AUC) of VAS, patient satisfaction score (PSS), the rates of treatment failure (RTF), and adverse events (AEs) and serious adverse event (SAEs) were recorded during the period of trial. Result. A total of 345 patients were enrolled in the full analysis set (FAS), and of 326 participants were valid data set (VDS). Demographic characteristics, disease features, and medical history of patients were not significantly different between groups. Total morphine consumption of the IVIB 400 mg group (11.14 ± 7.14 mg; P = 0.0011) and the IVIB 800 mg group (11.29 ± 6.45 mg; P = 0.0014) was significantly reduced compared with the placebo group (14.51 ± 9.19 mg) for 24 h postoperatively, there was no significant difference between the IVIB 400 mg and IVIB 800 mg groups (P = 0.9997). The placebo group had significantly higher VAS and the AUCs of VAS than those in the IVIB 400 mg and the IVIB 800 mg groups at rest and movement for 24 h postoperatively (P &lt; 0.05), and there was no significant difference between the IVIB 400 mg and IVIB 800 mg groups (P &gt; 0.05). RTF was slightly higher in the placebo group than IVIB 400 mg group and 800 mg group, and no statistical significance (P &lt; 0.690). PSS in the IVIB 400 mg (P = 0.0092) and the IVIB 800 mg groups (P = 0.0011) was higher than the placebo group for pain management, there was also no significant difference between the IVIB 400 mg and IVIB 800 mg groups (P = 0.456). The incidence of RTF (P = 0.690) and AEs (P &gt; 0.05) were not different among the three groups. Conclusion. Intermittent IV administration of ibuprofen 400 mg or 800 mg within 24 h after surgery in patients undergoing abdominal and orthopedic surgery significantly decreased morphine consumption and relieved pain, without increasing the incidence of AEs.</description><subject>Acute Pain - drug therapy</subject><subject>Acute Pain - etiology</subject><subject>Analgesics</subject><subject>Analgesics - therapeutic use</subject><subject>Analgesics, Opioid - therapeutic use</subject><subject>Anesthesia</subject><subject>Blood pressure</subject><subject>Bone surgery</subject><subject>Clinical trials</subject><subject>Dosage and administration</subject><subject>Double-Blind Method</subject><subject>Drug dosages</subject><subject>Drug therapy</subject><subject>Humans</subject><subject>Ibuprofen</subject><subject>Ibuprofen - therapeutic use</subject><subject>Medical personnel</subject><subject>Morphine</subject><subject>Morphine - therapeutic use</subject><subject>Narcotics</subject><subject>Nausea</subject><subject>Nervous system</subject><subject>Nonsteroidal anti-inflammatory drugs</subject><subject>Orthopedics</subject><subject>Pain management</subject><subject>Pain, Postoperative</subject><subject>Pain, Postoperative - drug therapy</subject><subject>Pain, Postoperative - etiology</subject><subject>Patient satisfaction</subject><subject>Pharmacology, Experimental</subject><subject>Physiological aspects</subject><subject>Postoperative period</subject><subject>Pruritus</subject><subject>Self evaluation</subject><subject>Testing</subject><subject>Urinary retention</subject><subject>Vomiting</subject><issn>1203-6765</issn><issn>1918-1523</issn><issn>1918-1523</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNp9kl1rFDEUhgdRbK3eeS0BQQSdNh_zkfFG1rXqQMVF6vVwJnOym5JN1mSmUn-Sv9KsW2tXRAJJSJ7znuScN8seM3rMWFmecMrFSV1XsqbFneyQNUzmrOTibtpzKvKqrsqD7EGMF5QWTFJxPzsQVcMrUTeH2Y-ZA7vEaBQ51dooUFfEa9K6McAlOj9F0vbTJniNjhhHxhWS84AwrtGNW3Lh4-g3GGA0l0hmahqRLMC4V2RGFiuISNq2JR8nOxqVQjCQz-AGvzbfcSALCwp7n899yuetxeGtn3qL-Rtr3EDmaU5PsimjAfswu6fBRnx0vR5lX96dns8_5Gef3rfz2VmuKibGvNRcMSyg7queF4yXAH05NIrJEijWvFeKlSALaHrR1xUOQlZSUFlKaITWQhxl7U538HDRbYJZQ7jqPJju14EPyw5C-o3Fri4p5aB70E1V1Ez2TFdCKQCtNBtSE46y1zutzdSvcdhWIIDdE92_cWbVLf1lxyhlBSubpPD8WiH4rxPGsVubqNBacJi60_FayropJS8S-vQv9MJPIfV3R3HR0IL_oZaQfmCc9imx2op2M8mKSlaN3Bbh-B9UGgOujfIOtUnnewHPbgWsEOy4it5Oo_Eu7oMvd6AKPsaA-qYajHZbR3dbR3fXjk74k9sVvIF_WzgBL3bAKlkGvpn_y_0Etf3-BQ</recordid><startdate>20230307</startdate><enddate>20230307</enddate><creator>Zhou, Hong-Su</creator><creator>Li, Ting-Ting</creator><creator>Pi, Yu</creator><creator>Wang, Ting-Hua</creator><creator>Liu, Fei</creator><creator>Xiong, Liu-Lin</creator><general>Hindawi</general><general>John Wiley &amp; Sons, Inc</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>4U-</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FQ</scope><scope>8FV</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M3G</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-3337-8168</orcidid><orcidid>https://orcid.org/0000-0002-2499-7605</orcidid><orcidid>https://orcid.org/0000-0003-2012-8936</orcidid><orcidid>https://orcid.org/0000-0002-1623-5969</orcidid><orcidid>https://orcid.org/0000-0001-6041-6719</orcidid><orcidid>https://orcid.org/0000-0002-9970-1338</orcidid></search><sort><creationdate>20230307</creationdate><title>Analgesic Efficacy of Intravenous Ibuprofen in the Treatment of Postoperative Acute Pain: A Phase III Multicenter Randomized Placebo-ControlledDouble-Blind Clinical Trial</title><author>Zhou, Hong-Su ; Li, Ting-Ting ; Pi, Yu ; Wang, Ting-Hua ; Liu, Fei ; Xiong, Liu-Lin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c613t-5f2c1e4a7b6b24125aab5d9c185a0e72bcc15a84a9b3b76ed386830858a93ff33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Acute Pain - drug therapy</topic><topic>Acute Pain - etiology</topic><topic>Analgesics</topic><topic>Analgesics - therapeutic use</topic><topic>Analgesics, Opioid - therapeutic use</topic><topic>Anesthesia</topic><topic>Blood pressure</topic><topic>Bone surgery</topic><topic>Clinical trials</topic><topic>Dosage and administration</topic><topic>Double-Blind Method</topic><topic>Drug dosages</topic><topic>Drug therapy</topic><topic>Humans</topic><topic>Ibuprofen</topic><topic>Ibuprofen - therapeutic use</topic><topic>Medical personnel</topic><topic>Morphine</topic><topic>Morphine - therapeutic use</topic><topic>Narcotics</topic><topic>Nausea</topic><topic>Nervous system</topic><topic>Nonsteroidal anti-inflammatory drugs</topic><topic>Orthopedics</topic><topic>Pain management</topic><topic>Pain, Postoperative</topic><topic>Pain, Postoperative - drug therapy</topic><topic>Pain, Postoperative - etiology</topic><topic>Patient satisfaction</topic><topic>Pharmacology, Experimental</topic><topic>Physiological aspects</topic><topic>Postoperative period</topic><topic>Pruritus</topic><topic>Self evaluation</topic><topic>Testing</topic><topic>Urinary retention</topic><topic>Vomiting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhou, Hong-Su</creatorcontrib><creatorcontrib>Li, Ting-Ting</creatorcontrib><creatorcontrib>Pi, Yu</creatorcontrib><creatorcontrib>Wang, Ting-Hua</creatorcontrib><creatorcontrib>Liu, Fei</creatorcontrib><creatorcontrib>Xiong, Liu-Lin</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>University Readers</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Canadian Business &amp; Current Affairs Database</collection><collection>Canadian Business &amp; Current Affairs Database (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>CBCA Reference &amp; Current Events</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Pain Research and Management</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhou, Hong-Su</au><au>Li, Ting-Ting</au><au>Pi, Yu</au><au>Wang, Ting-Hua</au><au>Liu, Fei</au><au>Xiong, Liu-Lin</au><au>Kim, Young-Kug</au><au>Young-Kug Kim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Analgesic Efficacy of Intravenous Ibuprofen in the Treatment of Postoperative Acute Pain: A Phase III Multicenter Randomized Placebo-ControlledDouble-Blind Clinical Trial</atitle><jtitle>Pain Research and Management</jtitle><addtitle>Pain Res Manag</addtitle><date>2023-03-07</date><risdate>2023</risdate><volume>2023</volume><spage>7768704</spage><epage>12</epage><pages>7768704-12</pages><issn>1203-6765</issn><issn>1918-1523</issn><eissn>1918-1523</eissn><abstract>Objective. To evaluate the analgesic efficacy and safety of different does of intravenous ibuprofen (IVIB) in the treatment of postoperative acute pain. Methods. Patients with an intravenous (IV) patient-controlled analgesia device after abdominal or orthopedic surgery were randomly divided into placebo, IVIB 400 mg, and IVIB 800 mg groups. The first dosage of study medicines was given intravenously 30 minutes (min) before surgery ended, followed by six hours (h) intervals for a total of eight doses following surgery. The demographic characteristics and procedure data, cumulative morphine consumption, the visual analog scale (VAS), the area under the curve (AUC) of VAS, patient satisfaction score (PSS), the rates of treatment failure (RTF), and adverse events (AEs) and serious adverse event (SAEs) were recorded during the period of trial. Result. A total of 345 patients were enrolled in the full analysis set (FAS), and of 326 participants were valid data set (VDS). Demographic characteristics, disease features, and medical history of patients were not significantly different between groups. Total morphine consumption of the IVIB 400 mg group (11.14 ± 7.14 mg; P = 0.0011) and the IVIB 800 mg group (11.29 ± 6.45 mg; P = 0.0014) was significantly reduced compared with the placebo group (14.51 ± 9.19 mg) for 24 h postoperatively, there was no significant difference between the IVIB 400 mg and IVIB 800 mg groups (P = 0.9997). The placebo group had significantly higher VAS and the AUCs of VAS than those in the IVIB 400 mg and the IVIB 800 mg groups at rest and movement for 24 h postoperatively (P &lt; 0.05), and there was no significant difference between the IVIB 400 mg and IVIB 800 mg groups (P &gt; 0.05). RTF was slightly higher in the placebo group than IVIB 400 mg group and 800 mg group, and no statistical significance (P &lt; 0.690). PSS in the IVIB 400 mg (P = 0.0092) and the IVIB 800 mg groups (P = 0.0011) was higher than the placebo group for pain management, there was also no significant difference between the IVIB 400 mg and IVIB 800 mg groups (P = 0.456). The incidence of RTF (P = 0.690) and AEs (P &gt; 0.05) were not different among the three groups. Conclusion. Intermittent IV administration of ibuprofen 400 mg or 800 mg within 24 h after surgery in patients undergoing abdominal and orthopedic surgery significantly decreased morphine consumption and relieved pain, without increasing the incidence of AEs.</abstract><cop>United States</cop><pub>Hindawi</pub><pmid>36926379</pmid><doi>10.1155/2023/7768704</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-3337-8168</orcidid><orcidid>https://orcid.org/0000-0002-2499-7605</orcidid><orcidid>https://orcid.org/0000-0003-2012-8936</orcidid><orcidid>https://orcid.org/0000-0002-1623-5969</orcidid><orcidid>https://orcid.org/0000-0001-6041-6719</orcidid><orcidid>https://orcid.org/0000-0002-9970-1338</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1203-6765
ispartof Pain Research and Management, 2023-03, Vol.2023, p.7768704-12
issn 1203-6765
1918-1523
1918-1523
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10014159
source MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection); PubMed Central; Alma/SFX Local Collection
subjects Acute Pain - drug therapy
Acute Pain - etiology
Analgesics
Analgesics - therapeutic use
Analgesics, Opioid - therapeutic use
Anesthesia
Blood pressure
Bone surgery
Clinical trials
Dosage and administration
Double-Blind Method
Drug dosages
Drug therapy
Humans
Ibuprofen
Ibuprofen - therapeutic use
Medical personnel
Morphine
Morphine - therapeutic use
Narcotics
Nausea
Nervous system
Nonsteroidal anti-inflammatory drugs
Orthopedics
Pain management
Pain, Postoperative
Pain, Postoperative - drug therapy
Pain, Postoperative - etiology
Patient satisfaction
Pharmacology, Experimental
Physiological aspects
Postoperative period
Pruritus
Self evaluation
Testing
Urinary retention
Vomiting
title Analgesic Efficacy of Intravenous Ibuprofen in the Treatment of Postoperative Acute Pain: A Phase III Multicenter Randomized Placebo-ControlledDouble-Blind Clinical Trial
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T12%3A40%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Analgesic%20Efficacy%20of%20Intravenous%20Ibuprofen%20in%20the%20Treatment%20of%20Postoperative%20Acute%20Pain:%20A%20Phase%20III%20Multicenter%20Randomized%20Placebo-ControlledDouble-Blind%20Clinical%20Trial&rft.jtitle=Pain%20Research%20and%20Management&rft.au=Zhou,%20Hong-Su&rft.date=2023-03-07&rft.volume=2023&rft.spage=7768704&rft.epage=12&rft.pages=7768704-12&rft.issn=1203-6765&rft.eissn=1918-1523&rft_id=info:doi/10.1155/2023/7768704&rft_dat=%3Cgale_doaj_%3EA814686983%3C/gale_doaj_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2788239042&rft_id=info:pmid/36926379&rft_galeid=A814686983&rft_doaj_id=oai_doaj_org_article_75002afbaf964718b1f63ccaafcf1d52&rfr_iscdi=true